INTELLIGENT BIO SOLUTIONS INC.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended March 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Cash flows from Operating Activities | |||
| Net loss | $(7,502,270) | $(7,395,572) | |
| Adjustments to reconcile net loss to cash used in operating activities: | |||
| Depreciation and amortization | 726,206 | 746,508 | |
| Amortization of right-of-use assets | 181,371 | 178,891 | |
| Provision for inventory obsolescence | - | 69,279 | |
| Share-based compensation | 226,045 | 218,305 | |
| Non-cash refund of research and development (R&D) expenditure claims | (156,011) | (112,293) | |
| Fair value gain on revaluation of holdback Series C Preferred Stock | - | (175,738) | |
| Non-cash other operating activities | 82,288 | 14,812 | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (81,259) | (66,040) | |
| Inventories | 94,049 | 102,002 | |
| Grant receivable / deferred grant income | (207,987) | - | |
| Research and development tax incentive receivable | 5,020 | 166,287 | |
| Other current assets | (87,884) | - | |
| Accounts payable and accrued expenses | (554,849) | (214,308) | |
| Long-term employee benefit liabilities | 9,057 | 5,384 | |
| Operating lease liabilities | (201,132) | (165,072) | |
| Net cash used in operating activities | (7,467,356) | (6,627,555) | |
| Cash flows from Investing Activities | |||
| Amount invested on construction in progress | (23,321) | (54,118) | |
| Net cash used in investing activities | (23,321) | (54,118) | |
| Cash flows from Financing Activities | |||
| Proceeds from issuance of common stock and warrants, net of issuance costs | 3,987,869 | 3,786,164 | |
| Proceeds from exercise of warrants, net of issuance costs | 7,939 | 1,651,498 | |
| Proceeds from private placement, net of issuance costs | - | 9,117,581 | |
| Net cash provided by financing activities | 3,995,808 | 14,555,243 | |
| Effect of foreign exchange rates on cash and cash equivalents | (2,117) | (13,291) | |
| Net (decrease) increase in cash and cash equivalents | (3,496,986) | 7,860,279 | |
| Cash and cash equivalents, beginning of period | 6,304,098 | 1,537,244 | |
| Cash and cash equivalents, end of period | $2,807,112 | $9,397,523 | |
| Non-cash investing and financing activities | |||
| Equity issuance costs in accounts payable and accrued expenses | $148,205 | $185,688 | |
| Conversion of preferred shares into common shares | $ | - | $57,287 |
| Conversion of holdback Series C Preferred Stock into common stock | $ | - | $32,762 |
| Issuance of common stock upon cashless exercise of Series F warrants | $6 | $6,551 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.